Search

KR-20260065094-A - The use of probiotic lactic acid bacteria for ameliorating irritable bowel syndrome through regulation of the enteric nervous system

KR20260065094AKR 20260065094 AKR20260065094 AKR 20260065094AKR-20260065094-A

Abstract

The present invention relates to the use of Limosyl Lactobacillus fermentum strains, Lacticase Bacillus rhamnosus strains, or Lactiplantibacillus plantarum strains for improving irritable bowel syndrome through the regulation of the intestinal nervous system. When using the composition of the present invention, irritable bowel syndrome can be effectively prevented, improved, or treated.

Inventors

  • 김지희
  • 박수제
  • 신창훈

Assignees

  • 주식회사 종근당바이오

Dates

Publication Date
20260508
Application Date
20241031

Claims (11)

  1. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome (IBS), comprising one or more strains selected from the group consisting of Limosilactobacillus fermentum , Lacticaseibacillus rhamnosus , and Lactiplantibacillus plantarum .
  2. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the Limosilactobacillus fermentum is Limosilactobacillus fermentum SRK414 (accession number KCTC 13687BP), the Lacticaseibacillus rhamnosus is Lacticaseibacillus rhamnosus LDTM7511 (accession number KCTC 18735P), or the Lactiplantibacillus plantarum is Lactiplantibacillus plantarum CKDB008 (accession number KCTC 13673BP).
  3. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the above-mentioned Limosyl Lactobacillus fermentum comprises the 16S RNA base sequence of SEQ ID NO. 1, the above-mentioned Lacticaseibacillus rhamnosus comprises the 16S RNA base sequence of SEQ ID NO. 2, or the above-mentioned Lactiplantibacillus plantarum comprises the 16S RNA base sequence of SEQ ID NO. 3.
  4. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the strain has characteristics of improving the level of tight junctions in intestinal cells, decreasing the level of the Abdominal Escape Reflex (AER), decreasing the blood cortisol concentration, decreasing the blood IgE concentration, decreasing the intestinal serotonin concentration, decreasing the intestinal IFN-γ concentration, or a combination thereof.
  5. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the strain is a live strain, a dead strain, an inactivated strain, a culture of the strain, a concentrate of the culture, a dried product of the culture, a pulverized product of the strain, an extract of the strain, a supernatant of the culture, or a combination thereof.
  6. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the concentration of the strain is 1 x 10⁷ CFU/mL to 1 x 10¹⁰ CFU/mL.
  7. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the irritable bowel syndrome is irritable bowel syndrome caused by an abnormality in the enteric nervous system, an abnormality in intestinal serotonin metabolism, or a combination thereof.
  8. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the irritable bowel syndrome is accompanied by visceral hypersensitivity, leaky gut syndrome, or a combination thereof.
  9. A pharmaceutical composition for the prevention or treatment of irritable bowel syndrome according to claim 1, wherein the irritable bowel syndrome is diarrheal-type irritable bowel syndrome (IBS-D) or mixed-type irritable bowel syndrome (IBS-M).
  10. A food composition for the prevention or improvement of Irritable Bowel Syndrome (IBS), comprising one or more strains selected from the group consisting of Limosilactobacillus fermentum , Lacticaseibacillus rhamnosus , and Lactiplantibacillus plantarum .
  11. A feed composition for the prevention or improvement of Irritable Bowel Syndrome (IBS), comprising one or more strains selected from the group consisting of Limosilactobacillus fermentum , Lacticaseibacillus rhamnosus , and Lactiplantibacillus plantarum .

Description

Use of probiotic lactic acid bacteria for ameliorating irritable bowel syndrome through regulation of the enteric nervous system The present invention relates to the use of Limosil Lactobacillus fermentum strain, Lacticase Bacillus rhamnosus strain, or Lactiplantibacillus plantarum strain for improving irritable bowel syndrome through regulation of the intestinal nervous system. Functional gastrointestinal disorders are very common, affecting approximately 40% of the global population, and can significantly impact daily life and quality of life. Among these disorders, Irritable Bowel Syndrome (IBS) is a functional colon disorder characterized by chronic abdominal pain, discomfort, and changes in bowel habits (diarrhea, constipation, or alternation of both). It is known to occur without structural abnormalities or inflammatory changes within the intestines. While the exact cause of IBS has not yet been clearly identified, various studies report that complex factors interact to trigger symptoms. In particular, it has been found to be closely related to dysregulation of the gut-brain axis and is reported to be caused by intestinal inflammation, immune responses, dysregulation of the enteric nervous system, and an imbalance of the gut microbiome. Visceral hypersensitivity is one of the major pathological mechanisms in IBS, referring to a state of excessive sensitivity to stimuli felt by organs (primarily the intestines and stomach). This is a factor that causes pain or discomfort even from normal stimuli occurring within the digestive tract (such as bloating after food intake). This visceral hypersensitivity is caused by abnormalities in the gut-brain axis, that is, problems in the neural interaction between the gut and the brain, resulting in an abnormally sensitive response to stimuli, and can be triggered or exacerbated by inflammation, infection, stress, etc. The treatment of irritable bowel syndrome requires a multifaceted approach, and it is reported that there is currently no single treatment effective for all patients. While various pharmacological and non-pharmacological therapies are used for symptom management, personalized treatment tailored to the patient's specific symptoms is necessary, and psychological therapy also plays an important role. Pharmacological treatments include anticonvulsants to suppress excessive intestinal contractions, tricyclic antidepressants prescribed for pain control, and serotonin receptor agonists (5-HT3 receptor antagonists) used to normalize intestinal motility. Dietary therapy (FODMAP diet) and lifestyle modifications are recommended for patients ranging from mild to severe cases, and probiotic intake has also been shown to be effective in alleviating symptoms in some patients. To verify the efficacy of these therapeutic agents and probiotics, methods to improve the condition in animal models that mimic human irritable bowel syndrome (IBS) are being studied. By inducing physical stress, chemical stress, bacterial and parasitic infections, or complex stress in animal subjects, researchers are inducing characteristic symptoms of IBS, such as visceral hypersensitivity, to verify the improvement effects of candidate substances. Among various animal models, one method that mimics IBS by inducing chemical stress involves directly injecting chemicals into the colon via enema therapy to increase intestinal sensitivity and induce inflammation. A model that induces IBS by injecting low-concentration acetic acid into the colon is reported to mimic IBS through a mechanism that increases intestinal sensitivity by inducing inflammation and visceral hypersensitivity along with damage to the colonic mucosa. In a study published by La et al. in 2003, 4% acetic acid was injected into the colon of male rats to induce colonitis, and hypersensitivity to rectal distension was observed by evaluating intestinal responsiveness even after the inflammation subsided. In particular, the severity of symptoms can be assessed by measuring the degree of the abdominal withdrawal reflex (AWR) as an indicator of visceral hypersensitivity. The acetic acid-induced irritable bowel syndrome animal model described in this study demonstrated a pattern of persistent visceral hypersensitivity after inflammation and proved to be a useful animal model for research on post-inflammatory irritable bowel syndrome by confirming characteristics such as increased bowel activity and the expulsion of stools of unclear form, including diarrhea, under stressful conditions. Research on probiotics based on irritable bowel syndrome and the gut-brain axis has recently been receiving significant attention. While existing studies have shown some positive results regarding the effects of probiotics on irritable bowel syndrome, their efficacy may vary depending on the symptoms or types of the condition. Furthermore, it has not yet been clearly determined which probiotic strain is most effective, and further research on the mechanis